DUBLIN–(BUSINESS WIRE)–The report “In Vitro Diagnostics (IVD) in Malaysia, Singapore and Indonesia, 2022” has been added ResearchAndMarkets.com’s sacrifice
The Asia Pacific (APAC) region is a rapidly growing in vitro diagnostics (IVD) market, which is witnessing increasing focus from leading global players in the market. Southeast Asia has been identified as one of the key regions in the APAC region that offers significant opportunities for IVD companies.
This report focuses on three IVD markets in Southeast Asia: Malaysia, Indonesia and Singapore. These three countries together represent a fast-growing geographic region that offers significant opportunities for IVD companies. The total population of these three countries is over 310 million, which is close to the population of the United States.
Among these three countries, Singapore has established world-class health service capabilities in terms of infrastructure as well as skilled manpower. Although the population is less than 6 million, the Singapore market is attractive to IVD companies and it has become a medical tourism hub in the region.
Indonesia, on the other hand, is a country with a huge population of around 275 million people. The country is making significant strides to improve its healthcare infrastructure, which offers significant opportunities for IVD companies. The Malaysian market, with a population of around 32 million falls between these two countries, both in terms of health service capabilities and growth potentials.
In Vitro Diagnostics (IVD) in Malaysia, Singapore, and Indonesia, 2022 covers the following segments:
-
POC
-
Clinical chemistry
-
Immunoassays
-
Molecular assays
-
Hematology
-
Coagulation
-
Microbiology and Virology
-
Blood test and typing
-
Histology and cytology
The report also profiles key companies in the market:
-
Abbott Diagnostics
-
ARKRAY
-
Beckman Coulter, Inc. / Danaher
-
Becton, Dickinson and Company (BD)
-
The shares of BioCytech Corporation
-
BioMerieux Inc.
-
The history of Bio-Rad Laboratories, Inc.
-
Caris Life Sciences
-
Cephei
-
The capitalization of CTK Biotech Inc
-
Danaher Corporation
-
Dexcom
-
DiaSorin SpA
-
Grifols SA
-
Healgen Scientific LLC
-
Hologic, Inc.
-
Horiba Medical
-
Lucence Diagnostics
-
Medical Innovation Ventures Sdn. Bhd. (mediven)
-
Mindray (Shenzhen Mindray Bio-Medical Electronics Co., Ltd.)
-
MiRXES Pte Ltd.
-
The history of OraSure Technologies, Inc.
-
Ortho Clinical Diagnostics (Ortho)
-
PerkinElmer, Inc. (PE)
-
QIAGEN
-
Reszon Diagnostics International
-
Roche Diagnostics
-
Sysmex Corporation Capitalization
-
Vela diagnostics
-
Veredus Laboratories Pte Ltd
Key topics covered:
Chapter 1: Executive Summary
Chapter 2: COVID-19 Testing Market Trends
Chapter 3: Point-of-care tests
Chapter 4: Core Lab and Clinical Chemistry
Chapter 5: Immunoassays
Chapter 6: Molecular Assays
Chapter 7: Hematology
Chapter 8: Coagulation
Chapter 9: Microbiology and Virology
Chapter 10: Blood Banking Services
Chapter 11: Histology and Cytology
Chapter 12: Company Profiles
For more information on this report visit https://www.researchandmarkets.com/r/a33wbm
